Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages

Cellular Immunology

Volumn 216, Issue 1-2, 2002, Pages 93-101

  Jonsson, Charlotte A ^a   Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

IC 21 macrophages; IL 1 ; LDH; MPA; NO2 ; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GUANOSINE; INOSINATE DEHYDROGENASE; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MYCOPHENOLIC ACID; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL LINE; CELL LYSATE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; ENZYME SYNTHESIS; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT;

ANIMALS; CELL DIVISION; CELL LINE; CULTURE MEDIA; ENZYME INHIBITORS; GUANOSINE; IMP DEHYDROGENASE; INTERLEUKIN-1; L-LACTATE DEHYDROGENASE; MACROPHAGES, PERITONEAL; MICE; MYCOPHENOLIC ACID; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE;

EID: 0036400419     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(02)00502-6     Document Type: Article

References (48)

1. R.W. McMurray, V. Harisdangkul, Mycophenolate mofetil: selective T cell inhibition, Am. J. Med. Sci. 323 (2002) 194-196.
2. M. Behrend, Mycophenolate mofetil: suggested guidelines for use in kidney transplantation, BioDrugs 15 (2001) 37-53.
3. T.M. Chan, F.K. Li, C.S. Tang, R.W. Wong, G.X. Fang, Y.L. Ji, C.S. Lau, A.K. Wong, M.K. Tong, K.W. Chan, K.N. Lai, Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group, N. Engl. J. Med. 343 (2000) 1156-1162.
4. C.A. Jonsson, L. Svensson, H. Carlsten, Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice, Clin. Exp. Immunol. 116 (1999) 534-541.
5. M.C. Van Bruggen, B. Walgreen, T.P. Rijke, J.H. Berden, Attenuation of murine lupus nephritis by mycophenolate mofetil, J. Am. Soc. Nephrol. 9 (1998) 1407-1415.
6. C.A. Jonsson, M. Erlandsson, L. Svensson, J. Mölne, H. Carlsten, Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice, Cell. Immunol. 197 (1999) 136-144.
7. D. Corna, M. Morigi, D. Facchinetti, T. Bertani, C. Zoja, G. Remuzzi, Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease, Kidney Int. 51 (1997) 1583-1589.
8. R.W. McMurray, K.B. Elbourne, A. Lagoo, S. Lal, Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus, J. Rheumatol. 25 (1998) 2364-2370.
9. C.A. Jonsson, H. Carlsten, Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice, Clin. Exp. Immunol. 124 (2001) 486-491.
10. M.D. Sintchak, E. Nimmesgern, The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors, Immunopharmacology 47 (2000) 163-184.
11. A.C. Allison, E.M. Eugui, Mycophenolate mofetil and its mechanisms of action, Immunopharmacology 47 (2000) 85-118.
12. A.C. Allison, T. Hovi, R.W. Watts, A.D. Webster, The role of de novo purine synthesis in lymphocyte transformation, Ciba Found Symp. (1977) 207-224.
13. A.C. Allison, T. Hovi, R.W. Watts, A.D. Webster, Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation, Lancet 2 (1975) 1179-1183.
14. A.C. Allison, E.M. Eugui, The design and development of an immunosuppressive drug, mycophenolate mofetil, Springer Semin. Immunopathol. 14 (1993) 353-380.
15. J.A. Sokoloski, O.C. Blair, A.C. Sartorelli, Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5′-phosphate dehydrogenase, Cancer Res. 46 (1986) 2314-2319.
16. R.V. Waters, D. Webster, A.C. Allison, Mycophenolic acid and some antioxidants induce differentiation of monocytic lineage cells and augment production of the IL-1 receptor antagonist, Ann. N. Y. Acad. Sci. 696 (1993) 185-196.
17. R.G. Cohn, A. Mirkovich, B. Dunlap, P. Burton, S.H. Chiu, E. Eugui, J.P. Caulfield, Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines, Transplantation 68 (1999) 411-418.
18. J. Mauel, V. Defendi, Infection and transformation of mouse peritoneal macrophages by simian virus 40, J. Exp. Med. 134 (1971) 335-350.
19. A. Galan, L. Garcia-Bermejo, N.E. Vilaboa, E. de Blas, P. Aller, Uncoupling of apoptosis and Jun/AP-1 activity in human promonocytic cells treated with DNA-damaging and stress-inducing agents, Eur. J. Cell Biol. 79 (2000) 1-9.
20. A. von Knethen, A. Lotero, B. Brune, Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression, Oncogene 17 (1998) 387-394.
21. J.W. van't Wout, I. Linde, P.C. Leijh, R. van Furth, Effect of irradiation, cyclophosphamide, and etoposide (VP-16) on number of peripheral blood and peritoneal leukocytes in mice under normal conditions and during acute inflammatory reaction, Inflammation 13 (1989) 1-14.
22. 15N]nitrate in biological fluids, Anal. Biochem. 126 (1982) 131-138.
23. M.H. Foster, V.R. Kelley, Lupus nephritis: update on pathogenesis and disease mechanisms, Semin. Nephrol. 19 (1999) 173-181.
24. T. Kuroiwa, E.G. Lee, Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney, Lupus 7 (1998) 597-603.
25. G.S. Hill, M. Delahousse, D. Nochy, P. Remy, F. Mignon, J.P. Mery, J. Bariety, Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages, Kidney Int. 59 (2001) 304-316.
26. M.A. Marletta, Nitric oxide: biosynthesis and biological significance, Trends Biochem. Sci. 14 (1989) 488-492.
27. A. Wanchu, M. Khullar, S.D. Deodhar, P. Bambery, A. Sud, Nitric oxide synthesis is increased in patients with systemic lupus erythematosus, Rheumatol. Int. 18 (1998) 41-43.
28. J.S. Wang, H.H. Tseng, D.F. Shih, H.S. Jou, L.P. Ger, Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis, Nephron 77 (1997) 404-411.
29. H.M. Belmont, D. Levartovsky, A. Goel, A. Amin, R. Giorno, J. Rediske, M.L. Skovron, S.B. Abramson, Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus, Arthritis Rheum. 40 (1997) 1810-1816.
30. J.B. Weinberg, D.L. Granger, D.S. Pisetsky, M.F. Seldin, M.A. Misukonis, S.N. Mason, A.M. Pippen, P. Ruiz, E.R. Wood, G.S. Gilkeson, The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine, J. Exp. Med. 179 (1994) 651-660.
31. S. Hortelano, M.J. Diaz-Guerra, A. Gonzalez-Garcia, E. Leonardo, C. Gamallo, L. Bosca, A.C. Martinez, Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mplpr/lpr mice, J. Immunol. 158 (1997) 1402-1408.
32. G.S. Gilkeson, J.S. Mudgett, M.F. Seldin, P. Ruiz, A.A. Alexander, M.A. Misukonis, D.S. Pisetsky, J.B. Weinberg, Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2, J. Exp. Med. 186 (1997) 365-373.
33. M. Senda, B. DeLustro, E. Eugui, Y. Natsumeda, Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells, Transplantation 60 (1995) 1143-1148.
34. S.S. Gross, R. Levi, Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle, J. Biol. Chem. 267 (1992) 25722-25729.
35. H.H. Schmidt, S.M. Lohmann, U. Walter, The nitric oxide and cGMP signal transduction system: regulation and mechanism of action, Biochim. Biophys. Acta 1178 (1993) 153-175.
36. G. Auerbach, H. Nar, The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase, Biol. Chem. 378 (1997) 185-192.
37. J.M. Boswell, M.A. Yui, D.W. Burt, V.E. Kelley, Increased tumor necrosis factor and IL-1β gene expression in the kidneys of mice with lupus nephritis, J. Immunol. 141 (1988) 3050-3054.
38. J.M. Boswell, M.A. Yui, S. Endres, D.W. Burt, V.E. Kelley, Novel and enhanced IL-1 gene expression in autoimmune mice with lupus, J. Immunol. 141 (1988) 118-124.
39. S. High, Protein translocation at the membrane of the endoplasmic reticulum, Prog. Biophys. Mol. Biol. 63 (1995) 233-250.
40. G. Palade, Intracellular aspects of the process of protein synthesis, Science 189 (1975) 347-358.
41. R. Ishisaka, N. Sato, K. Tanaka, T. Takeshige, H. Iwata, J. Klostergaard, T. Utsumi, A part of the transmembrane domain of pro-TNF can function as a cleavable signal sequence that generates a biologically active secretory form of TNF, J. Biochem. (Tokyo) 126 (1999) 413-420.
42. A. Rubartelli, F. Cozzolino, M. Talio, R. Sitia, A novel secretory pathway for interleukin-1β, a protein lacking a signal sequence, EMBO J. 9 (1990) 1503-1510.
43. C. Andrei, C. Dazzi, L. Lotti, M.R. Torrisi, G. Chimini, A. Rubartelli, The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles, Mol. Biol. Cell 10 (1999) 1463-1475.
44. K.A. Hogquist, E.R. Unanue, D.D. Chaplin, Release of IL-1 from mononuclear phagocytes, J. Immunol. 147 (1991) 2181-2186.
45. K.A. Hogquist, M.A. Nett, E.R. Unanue, D.D. Chaplin, Interleukin 1 is processed and released during apoptosis, Proc. Natl. Acad. Sci. USA 88 (1991) 8485-8489.
46. A.G. Wingren, O. Bjorkdahl, T. Labuda, L. Bjork, U. Andersson, U. Gullberg, G. Hedlund, H.O. Sjogren, T. Kalland, B. Widegren, M. Dohlsten, Fusion of a signal sequence to the interleukin-1β gene directs the protein from cytoplasmic accumulation to extracellular release, Cell. Immunol. 169 (1996) 226-237.
47. D.G. Perregaux, C.A. Gabel, Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism, J. Immunol. 160 (1998) 2469-2477.
48. D. Ferrari, S. Wesselborg, M.K.A. Bauer, K. Schulze-Osthoff, Extracellular ATP activates transcription factor NF-κB through the P2Z purinoreceptor by selectively targeting NF-κB p65, J. Cell Biol. 139 (1997) 1635-1643.